This antibody is B lineage specific and reacts with early B cell precursors, pre pre B cells, pre B cells, B cells, intermediate B cells, mature B cells and some plasmacytoid cells. Plasma cells were found to be negative. The antibody does not react with other haemopoïetic cells. The monoclonal antibody also reacts with pre B cell lines, B lymphoblastoid
cell lines and Burkitt cell lines, and with 50% of myeloma cell lines. Virtually all non T ALL, B CLL and B cell lymphomas were found to be positive, myeloma cells were found to be negative.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Flow Cyt: Use 20 µl for 106 cells.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Involvement in disease
Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.